Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Articles
Plexxikon Inc.
Headquarters:
Berkeley, CA, United States of America
Website:
N/A
Year Founded:
2000
Status:
Acquired
BioCentury
|
Nov 1, 2023
Management Tracks
Genentech’s Hardy to become CEO at BioMarin
Plus: BMS CEO Boerner appointed chair, and updates from Storm, Amarin, CTRL, Lakewood, Vesica and RS
Read More
BioCentury
|
Mar 11, 2023
Emerging Company Profile
Opna Bio: targeting FMRP to treat cancer
Company’s other five small molecules come from CEO Gideon Bollag’s former company, Plexxikon
Read More
BioCentury
|
Nov 30, 2022
Discovery & Translation
Acuitas’ pan-influenza mRNA vaccine; plus Opna links FMR1 to cancer and more
BioCentury’s roundup of translational news
Read More
BioCentury
|
Nov 22, 2022
Finance
Nov. 21 Quick Takes: Oncology company Opna launches with $38M
Plus: FogPharma raises another $178M and updates from Genmab and Replay
Read More
BioCentury
|
Nov 18, 2021
Management Tracks
D’Amelio to retire as Pfizer’s CFO
Plus: BioAge, bit bio, Volastra, Provention and more
Read More
BioCentury
|
Jul 2, 2021
Management Tracks
McKinsey alums Santos da Silva, Bodenstedt join MoonLake; plus Takeda, Plexxikon, Solid, EQRx, Cardior and more
Two months after Merck KGaA (Xetra:MRK) teamed up with BVF Partners to launch MoonLake Immunotherapeutics AG, the newco has hired McKinsey veterans Jorge Santos da Silva as CEO and
Read More
BioCentury
|
Apr 22, 2021
Management Tracks
Ceesay joins Coles’ Cerevel as president; plus updates from Replimune, Perceptive, Antiva, Vera, Patient Square, Zymeworks and more
Read More
BioCentury
|
May 24, 2019
Product Development
Why quizartinib hiccup at ODAC shouldn’t derail Daiichi’s 2025 cancer drug goals
Despite ODAC’s snub of quizartinib, Daiichi has several moves to make its 2025 cancer drug goals
Read More
BioCentury
|
Oct 27, 2017
Company News
Daiichi and MD Anderson partner to develop AML candidates
Read More
BioCentury
|
Dec 2, 2015
Company News
Management tracks
Read More
Items per page:
10
1 - 10 of 190
Help Center
Username
Request a Demo
Request Training
Ask a Question
Elevio by Dixa
Help